INHIBITORY CHECKPOINT MOLECULE

Clinical trials for INHIBITORY CHECKPOINT MOLECULE explained in plain language.

Never miss a new study

Get alerted when new INHIBITORY CHECKPOINT MOLECULE trials appear

Sign up with your email to follow new studies for INHIBITORY CHECKPOINT MOLECULE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New hope to slow advanced prostate cancer

Disease control Ongoing

This study is testing whether adding a new immunotherapy drug called lorigerlimab to standard chemotherapy (docetaxel) can help men with advanced prostate cancer live longer without their cancer getting worse. About 150 men whose cancer has spread and stopped responding to hormon…

Matched conditions: INHIBITORY CHECKPOINT MOLECULE

Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control

Last updated Mar 24, 2026 12:01 UTC

INHIBITORY CHECKPOINT MOLECULE

Get alerted when new INHIBITORY CHECKPOINT MOLECULE trials appear

New hope to slow advanced prostate cancer